Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed
Executive Summary
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
You may also be interested in...
Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy
Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.
Asia Executives On The Move: Comings And Goings At BeiGene, Harbour BioMed, TLC, GC Pharma
New Year brings a flurry of new executive moves in the life sciences sector in Asia Pacific, including the departure of BeiGene's chief commercial officer and a new chief strategy officer and CMO at Harbour Biomed.
AbbVie Defends Humira With Aggressive Discount In First EU Tender
AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.